NCT01142596View on ClinicalTrials.gov

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

May 25, 2010

Primary Completion Date

April 22, 2015

Study Completion Date

April 22, 2015

Conditions
Schizophrenia
Interventions
DRUG

Asenapine

Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID

DRUG

Placebo

Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)

Sponsors
All Listed Sponsors
collaborator

Meiji Seika Pharma Co., Ltd.

INDUSTRY

lead

Organon and Co

INDUSTRY